Handelsavisen
prelaunch
Companies ›Basic Materials ›CAPR.BO
CA
CAPR.BO — BSE (India) Non-Paper Containers & Packaging

Capr.Bo

$76,57
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-3,5 %
ROE
-14,4 %
Net margin
-8,3 %
Debt / equity
1,61
Beta
—
52w range
—
Volume
46
Day range
—
Prev close
$19,70
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

CAPR.BO operates in the Non-Paper Containers & Packaging industry, manufacturing and distributing packaging solutions for industrial and consumer goods.

Business. Capricor Therapeutics Inc (CAPR.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorBasic Materials
Business sectorApplied Resources
IndustryNon-Paper Containers & Packaging
Generated · model-assisted
Sell-side consensus
BUY10 analysts
10 buy0 hold0 sell
Avg 12m price target53,60

Analyst recommendations

10 analysts · consensus Buy
Buy10
Hold0
Sell0
12-month price target
53,60
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
10 analysts · indicative
Ownership→
Goldman Sachs Asset Management, L.P.
largest disclosed fund holder
Profitability→
-14,4 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CAPR.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CAPR.BO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Capricor Therapeutics Inc (CAPR.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorBasic Materials
    Business sectorApplied Resources
    IndustryNon-Paper Containers & Packaging
    AI synthesis
    GENERATED

    CAPR.BO's capital structure is highly leveraged, with a debt-to-equity ratio of 1.61, indicating significant reliance on debt financing. The company's liquidity position is weak, with a current ratio of 0.79 and only INR 6 million in cash and equivalents, far below the INR 6.95 billion in long-term debt. Free cash flow is negative at INR -280.7 million, suggesting insufficient cash generation to service debt obligations.

    Profitability metrics are sharply negative, with a return on equity of -14.39% and a return on assets of -4.96%, both well below industry norms for packaging firms. Operating income is negative at INR -264.5 million, and net income is INR -621.8 million, indicating a deep operating loss. Gross profit of INR 1.59 billion is insufficient to cover operating expenses, highlighting operational inefficiencies.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to regional economic downturns and supply chain disruptions. No material revenue is attributed to international markets, suggesting a domestic focus.

    Growth trajectory is negative, with no disclosed revenue growth in the latest period and a net loss of INR 621.8 million. Capital expenditures of INR -86.5 million indicate minimal investment in future capacity, which may hinder long-term growth. The company's operating cash flow of INR 902.3 million is insufficient to offset the negative free cash flow, signaling cash flow constraints.

    Risk factors include high leverage and negative net cash position, with total liabilities of INR 8.22 billion and total equity of INR 4.32 billion. Dilution risk is low, with no difference between basic and diluted shares outstanding. However, the company's negative net income and operating cash flow suggest potential for future dilution through debt financing or equity raises.

    Recent events include a significant operating loss and negative net income, as disclosed in the latest financial filing. No material events such as mergers, acquisitions, or regulatory actions were disclosed in the latest period. The company's financial health appears to be deteriorating, with no clear turnaround strategy evident in the latest data.

    Key takeaways
    • CAPR.BO is highly leveraged with a debt-to-equity ratio of 1.61 and negative net cash position.
    • The company is unprofitable, with a return on equity of -14.39% and a net loss of INR 621.8 million.
    • Revenue is concentrated in a single segment with no geographic diversification.
    • Free cash flow is negative at INR -280.7 million, indicating insufficient cash to service debt.
    • Growth is constrained by negative operating income and minimal capital expenditures.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Analysts project 164% upside to a mean price target of $53.60, signaling strong institutional confidence in future valuation.

    The company maintains a low leverage band with a debt-to-equity ratio of 0.164, indicating a conservative capital structure.

    A current ratio of 9.01 suggests robust short-term liquidity, minimizing immediate solvency concerns despite operating losses.

    Liquidity and dilution risks are assessed as low, providing a stable financial foundation for ongoing operations.

    Revenue reached $25.2 million in FY2024, demonstrating the company's ability to generate some operating income before recent declines.

    BEAR CASE · 1

    Cash conversion ratio of 0.61 is below the cohort median of 0.72, suggesting weaker ability to convert earnings into cash.

    In focus — financials by report

    Valuation

    Market price
    $76,57
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $4.32B
    Net cashⓘ
    -$6.95B
    Current ratioⓘ
    0.8
    Debt / equityⓘ
    1.6
    ROAⓘ
    -5.0%
    ROEⓘ
    -14.4%
    Cash conversionⓘ
    -145.0%
    CapEx / revenueⓘ
    -1.1%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
    Partners1

    Supply chain

    Vendors → CAPR ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSCAPRCAPRCapr.Bo1 entityNippon Shinyaku Co LtdUnclassifiedJP
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,40
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    10
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-07-27 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$38,00
    Mean$53,60
    Median$52,50
    High$63,00
    Spot$76,57
    −30.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-3,5 %Bottom quartile
    Net Margin-8,3 %Bottom quartile
    ROE-14,4 %Bottom quartile
    Capex / Rev-1,1 %Above P75
    D/E1,61Bottom quartile
    Cash Conv-1,45Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 152 314 sh19 exercises · 16 grants11 insiders
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Common StockDisposed 24 100 @ $3,18exercise · 2026-06-25
    • Krasney KarenEVP, GENERAL COUNSEL · Stock Option (Right to Buy) → Common StockDisposed 24 100 @ $3,18exercise · 2026-06-25
    • Krasney KarenEVP, GENERAL COUNSEL · Stock Option (Right to Buy) → Common StockDisposed 400 @ $3,18exercise · 2026-06-24
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Common StockDisposed 400 @ $3,18exercise · 2026-06-24
    • Krasney KarenEVP, GENERAL COUNSEL · Stock Option (Right to Buy) → Common StockDisposed 500 @ $3,18exercise · 2026-06-22
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Common StockDisposed 500 @ $3,18exercise · 2026-06-22
    • Maurer Michael TCHIEF COMMERCIAL OFFICER · Stock Option (Right to Buy) → Common StockAcquired 80 000 @ $29,36grant · 2026-05-26
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Common StockDisposed 3 000 @ $1,39exercise · 2026-05-18
    • Litvack FrankDirector · Stock Option (Right to Buy) → Common StockDisposed 3 937 @ $1,39exercise · 2026-05-13
    • Krasney KarenEVP, GENERAL COUNSEL · Stock Option (Right to Buy) → Common StockDisposed 25 000 @ $3,18exercise · 2026-05-01
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Common StockDisposed 25 000 @ $3,18exercise · 2026-05-01
    • Sabar Karimah EsDirector · Stock Option (Right to Buy) → Common StockDisposed 7 529 @ $3,18exercise · 2026-04-02
    • Sabar Karimah EsDirector · Stock Option (Right to Buy) → Common StockDisposed 53 735 @ $4,86exercise · 2026-04-01
    • Krasney KarenEVP, GENERAL COUNSEL · Stock Option (Right to Buy) → Common StockDisposed 21 488 @ $3,74exercise · 2026-03-31
    • Krasney KarenEVP, GENERAL COUNSEL · Stock Option (Right to Buy) → Common StockDisposed 2 819 @ $3,18exercise · 2026-03-31
    • Sabar Karimah EsDirector · Stock Option (Right to Buy) → Common StockDisposed 61 265 @ $4,86exercise · 2026-03-31
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Common StockDisposed 25 000 @ $3,18exercise · 2026-03-31
    • Krasney KarenEVP, GENERAL COUNSEL · Stock Option (Right to Buy) → Common StockDisposed 693 @ $1,39exercise · 2026-03-31
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Restricted Stock Units → Common StockAcquired 2 500grant · 2026-01-05
    • Krasney KarenEVP, GENERAL COUNSEL · Stock Option (Right to Buy) → Common StockAcquired 22 500 @ $24,81grant · 2026-01-05
    • Auwaerter Paul GisbertDirector · Stock Option (Right to Buy) → Common StockAcquired 15 500 @ $24,81grant · 2026-01-05
    • Auwaerter Paul GisbertDirector · Stock Option (Right to Buy) → Common StockAcquired 1 360 @ $24,81grant · 2026-01-05
    • Auwaerter Paul GisbertDirector · Stock Option (Right to Buy) → Common StockAcquired 5 420 @ $24,81grant · 2026-01-05
    • Gotwals Philip JDirector · Stock Option (Right to Buy) → Common StockAcquired 15 500 @ $24,81grant · 2026-01-05
    • Sabar Karimah EsDirector · Stock Option (Right to Buy) → Common StockAcquired 15 500 @ $24,81grant · 2026-01-05

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • CAPR.BO Market data — financials · 2026-05-27

    Ownership & reference

    Top holders

    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$28M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$66M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$34M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$11M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$6M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$13M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$23M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$74M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$6M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$13M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$4M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$2M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$3M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$4M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$8M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Frank I. LitvackExecutive Chairman of the Board
    • Linda MarbanPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 13 sellsnet -$8,4M5 insiders · last 365d
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockOther 24 100 @ $3,18$77K · 2026-06-25
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockSold 24 100 @ $30,38$732K · 2026-06-25
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Common StockOther 24 100 @ $3,18$77K · 2026-06-25
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Common StockSold 24 100 @ $30,38$732K · 2026-06-25
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockSold 400 @ $30,00$12K · 2026-06-24
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockOther 400 @ $3,18$1K · 2026-06-24
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Common StockOther 400 @ $3,18$1K · 2026-06-24
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Common StockSold 400 @ $30,00$12K · 2026-06-24
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Common StockOther 500 @ $3,18$2K · 2026-06-22
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Common StockSold 500 @ $30,00$15K · 2026-06-22
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockSold 500 @ $30,00$15K · 2026-06-22
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockOther 500 @ $3,18$2K · 2026-06-22
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Common StockOther 3 000 @ $1,39$4K · 2026-05-18
    • Litvack FrankDirector · Common StockOther 3 937 @ $1,39$5K · 2026-05-13
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Common StockSold 25 000 @ $31,70$793K · 2026-05-01
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockOther 25 000 @ $3,18$80K · 2026-05-01
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockSold 25 000 @ $31,70$793K · 2026-05-01
    • Bergmann AnthonyCHIEF FINANCIAL OFFICER · Common StockOther 25 000 @ $3,18$80K · 2026-05-01
    • Sabar Karimah EsDirector · Common StockSold 7 529 @ $32,00$241K · 2026-04-02
    • Sabar Karimah EsDirector · Common StockOther 7 529 @ $3,18$24K · 2026-04-02
    • Sabar Karimah EsDirector · Common StockSold 53 735 @ $31,03$1,7M · 2026-04-01
    • Sabar Karimah EsDirector · Common StockOther 53 735 @ $4,86$261K · 2026-04-01
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockOther 2 819 @ $3,18$9K · 2026-03-31
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockOther 21 488 @ $3,74$80K · 2026-03-31
    • Krasney KarenEVP, GENERAL COUNSEL · Common StockSold 25 000 @ $30,12$753K · 2026-03-31

    Short positioning

    15.6Mshares short+5.7% vs prior
    10.79days to cover
    33.6%short of daily vol
    66fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CAPR.BOCanonical
    BSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    CAPR4516.TNon-Paper Cont
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -96.5%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -74.5%Derived (calculated)
    • Return on assets (FY 2025-12-31): -29.5%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 148.9%Derived (calculated)
    • Current ratio (FY 2025-12-31): 9.01xDerived (calculated)
    • Return on equity (FY 2025-12-31): -34.4%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 100.5%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 2,450.3%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.16xDerived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 110.2%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 69.0%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 108.8%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -159.6%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -154.1%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -100.0%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -96.5%Derived (calculated)
    • EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
    • Operating income (annual): USD -108.14MSEC XBRL filing
    • Revenue (annual): USD 0SEC XBRL filing
    • R&D expense (annual): USD 84.45MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -2SEC XBRL filing
    • Shareholders' equity (annual): USD 305.79MSEC XBRL filing
    • Operating cash flow (annual): USD -69.81MSEC XBRL filing
    • Cash & equivalents (annual): USD 287.85MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-25 00:00 UTCINSIDER18 insider transactions — 2026-06 · net sell $1.4M 6 derivative
    2026-06-25 00:00 UTCINSIDER18 insider transactions — 2026-06 · net sell $1.4M 6 derivative
    2026-06-25INSIDERKrasney Karen transacted 24.1k sh — EVP, GENERAL COUNSEL ~$77k
    2026-06-25INSIDERBergmann Anthony transacted 24.1k sh — CHIEF FINANCIAL OFFICER ~$77k
    2026-06-25INSIDERBergmann Anthony sold 24.1k sh — CHIEF FINANCIAL OFFICER ~$732k
    2026-06-25INSIDERKrasney Karen sold 24.1k sh — EVP, GENERAL COUNSEL ~$732k
    2026-06-25INSIDERBergmann Anthony disposed of 24.1k sh Stock Option (Right to Buy) — CHIEF FINANCIAL OFFICER
    2026-06-25INSIDERKrasney Karen disposed of 24.1k sh Stock Option (Right to Buy) — EVP, GENERAL COUNSEL
    2026-06-24INSIDERKrasney Karen sold 400 sh — EVP, GENERAL COUNSEL ~$12k
    2026-06-24INSIDERKrasney Karen transacted 400 sh — EVP, GENERAL COUNSEL ~$1k
    2026-06-24INSIDERBergmann Anthony transacted 400 sh — CHIEF FINANCIAL OFFICER ~$1k
    2026-06-24INSIDERBergmann Anthony sold 400 sh — CHIEF FINANCIAL OFFICER ~$12k
    2026-06-24INSIDERBergmann Anthony disposed of 400 sh Stock Option (Right to Buy) — CHIEF FINANCIAL OFFICER
    2026-06-24INSIDERKrasney Karen disposed of 400 sh Stock Option (Right to Buy) — EVP, GENERAL COUNSEL
    2026-06-22INSIDERBergmann Anthony transacted 500 sh — CHIEF FINANCIAL OFFICER ~$2k
    2026-06-22INSIDERBergmann Anthony sold 500 sh — CHIEF FINANCIAL OFFICER ~$15k
    2026-06-22INSIDERKrasney Karen sold 500 sh — EVP, GENERAL COUNSEL ~$15k
    2026-06-22INSIDERKrasney Karen transacted 500 sh — EVP, GENERAL COUNSEL ~$2k
    2026-06-22INSIDERKrasney Karen disposed of 500 sh Stock Option (Right to Buy) — EVP, GENERAL COUNSEL
    2026-06-22INSIDERBergmann Anthony disposed of 500 sh Stock Option (Right to Buy) — CHIEF FINANCIAL OFFICER
    2026-06-08FILING8-K filing →
    2026-05-26 00:00 UTCINSIDER11 insider transactions — 2026-05 · net sell $1.4M 5 derivative
    2026-05-26 00:00 UTCINSIDER11 insider transactions — 2026-05 · net sell $1.4M 5 derivative
    2026-05-26INSIDERMaurer Michael T acquired 80.0k sh Stock Option (Right to Buy) — CHIEF COMMERCIAL OFFICER
    2026-05-18INSIDERBergmann Anthony transacted 3.0k sh — CHIEF FINANCIAL OFFICER ~$4k
    2026-05-18INSIDERBergmann Anthony disposed of 3.0k sh Stock Option (Right to Buy) — CHIEF FINANCIAL OFFICER
    2026-05-13FILING10-Q filing →
    2026-05-13INSIDERLitvack Frank transacted 3.9k sh — Director ~$5k
    2026-05-13INSIDERLitvack Frank disposed of 3.9k sh Stock Option (Right to Buy) — Director
    2026-05-12FILING8-K filing →
    2026-05-07FILING8-K filing →
    2026-05-01INSIDERBergmann Anthony sold 25.0k sh — CHIEF FINANCIAL OFFICER ~$793k
    2026-05-01INSIDERKrasney Karen transacted 25.0k sh — EVP, GENERAL COUNSEL ~$80k
    2026-05-01INSIDERKrasney Karen sold 25.0k sh — EVP, GENERAL COUNSEL ~$793k
    2026-05-01INSIDERBergmann Anthony transacted 25.0k sh — CHIEF FINANCIAL OFFICER ~$80k
    2026-05-01INSIDERKrasney Karen disposed of 25.0k sh Stock Option (Right to Buy) — EVP, GENERAL COUNSEL
    2026-05-01INSIDERBergmann Anthony disposed of 25.0k sh Stock Option (Right to Buy) — CHIEF FINANCIAL OFFICER
    2026-04-10FILINGDEF 14A filing →
    2026-04-02 00:00 UTCINSIDER6 insider transactions — 2026-04 · net sell $1.6M 2 derivative
    Showing the 40 most recent of 61 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage